Ciclesonide

Drug Profile

Ciclesonide

Alternative Names: Alvesco; Alvesco HFA; BTR-15; BTR-15K; BY 9010; Ciclesonide DPI; Ciclesonide I.S.; Ciclesonide pMDI; EL 876; Omnair; Omnaris; Omnaris HFA; RPR 251526; TBN-15; XRP 1526; Zetonna

Latest Information Update: 19 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nycomed
  • Developer Sunovion Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH; Teijin Pharma
  • Class Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 13 Jul 2017 Covis Pharma acquires US market rights of ciclesonide from Sunovion Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Perennial-allergic-rhinitis in United Kingdom (Intranasal, Aerosol)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in United Kingdom (Intranasal, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top